Transmedics Group Inc (TMDX) Stock Price, Quote & News

Company Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of s...

Industry: Medical Devices

Sector: Healthcare

Phone: 978 552 0900

Website: www.transmedics.com

Address:

200 Minuteman Road, Suite 302, Andover, United States

Lambster2 Aug. 5 at 1:13 AM

$TMDX TransMedics (NASDAQ: TMDX) Buy (1) ESG Score: 61/100 Price Target: $170.00 TMDX Advances Next-Generation OCS Heart Development with ENHANCE IDE Approval THE TD COWEN INSIGHT TMDX announced that the FDA has granted conditional approval of its Investigational Device Exemption (IDE) to initiate the next-generation OCS ENHANCE Heart clinical program. This landmark two-part trial is designed to expand the capabilities and clinical indications of the OCS Heart System. The study is expected to begin enrollment in the near term and will contribute clinical revenues in 2H'25.

0 · Reply

NeverPop Aug. 5 at 1:04 AM

$TMDX really curious. do institutions just trade amongst themselves when they own 100% of the float ( not including insiders)

1 · Reply

SodApOp_PIMPski Aug. 4 at 11:55 PM

$TMDX 50dma showing signs it could be new support... a close above 145 will bring a new ATH

0 · Reply

Kenwonc Aug. 4 at 7:10 PM

$TMDX Ty to all the shorts! Ty keep holding do not close.

0 · Reply

kindness123 Aug. 4 at 5:46 PM

$TMDX

0 · Reply

buylowandwait Aug. 4 at 5:03 PM

$TMDX Years of growth and profitability ahead, this will go past ATH soon. Shorts are doomed, not selling single share. The company is doing minimal lung and heart, the next-gen OCS will change that landscape !

0 · Reply

Lets_Go_Brndn Aug. 4 at 3:52 PM

$TMDX $150+ it’s coming !!!

0 · Reply

sk7887 Aug. 4 at 3:45 PM

$BLDE Interesting thought out there on Blade being a takeout candidate by $TMDX at a sweet premium: https://twitter.com/sean3333a/status/1952393903597850907?s=46&t=Eoegu7w60cNDYtBO28U9LQ

1 · Reply

TriGuy8542 Aug. 4 at 3:23 PM

$TMDX damn, well I guess I’ll have to load the boat when we see a dip, whenever that is

2 · Reply

SodApOp_PIMPski Aug. 4 at 3:08 PM

$TMDX running away

0 · Reply

TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial

Aug 1, 2025, 4:05 PM EDT - 3 days ago

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aug 1, 2025, 6:25 AM EDT - 3 days ago

TransMedics: Continued Strength Suggests Further Upside

Jul 31, 2025, 12:28 AM EDT - 5 days ago

TransMedics Group, Inc. (TMDX) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 5 days ago

TransMedics Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 4:05 PM EDT - 6 days ago

TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 25, 2025, 11:57 AM EDT - 10 days ago

Why TransMedics Remains A Buy Into 2026

Jul 23, 2025, 4:17 PM EDT - 12 days ago

This Company Transports Donated Organs. Its Stock Has Had a Roller-Coaster Ride.

Jul 16, 2025, 4:05 PM EDT - 19 days ago

TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025

Jul 14, 2025, 12:27 AM EDT - 22 days ago

TransMedics: Q2 Analyst Estimates Will Fall Short

Jun 23, 2025, 10:00 AM EDT - 6 weeks ago

TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy

Jun 17, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Connect

Jun 15, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out

Jun 12, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 2 months ago

TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect

Jun 1, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Investors to Inquire about Securities Investigation

May 29, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Investors to Reach Out

May 27, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Reach Out

May 25, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Connect

May 22, 2025, 10:00 AM EDT - 2 months ago

TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 21, 2025, 4:54 AM EDT - 2 months ago

TransMedics: Extremely Undervalued And Extremely Innovative

May 20, 2025, 4:05 PM EDT - 2 months ago

TransMedics to Present at Upcoming June Investor Conferences

May 13, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Shareholders to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 3 months ago

TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 9, 2025, 9:48 AM EDT - 3 months ago

TransMedics: Exceptional Q1 Undermines The Short Narrative

May 8, 2025, 10:40 PM EDT - 3 months ago

TransMedics Group, Inc. (TMDX) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 3 months ago

TransMedics Reports First Quarter 2025 Financial Results

Apr 24, 2025, 4:05 PM EDT - 3 months ago

TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 23, 2025, 4:23 AM EDT - 3 months ago

TransMedics: Get Some Exposure Despite Market Concerns

Apr 22, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Stockholders to Learn More About the Investigation

Apr 11, 2025, 7:43 AM EDT - 4 months ago

TMDX STOCK FRAUD: Did TransMedics Group Commit Securities Fraud? Investors are Notified to Contact BFA Law by the April 15 Court Deadline (NASDAQ:TMDX)

Apr 11, 2025, 2:06 AM EDT - 4 months ago

DEADLINE NEXT WEEK: Berger Montague Advises TransMedics (NASDAQ: TMDX) Investors to Contact the Firm Before April 15, 2025

Apr 10, 2025, 7:00 PM EDT - 4 months ago

Investor Reminder (TMDX): Kessler Topaz Meltzer & Check, LLP Reminds TransMedics Group, Inc. Investors of April 15, 2025 Deadline

Apr 10, 2025, 3:38 PM EDT - 4 months ago

TMDX STOCK NOTICE: TransMedics Group is being Sued for Fraud – Investors with Losses are Reminded to Contact BFA Law by April 15 Deadline

Apr 10, 2025, 10:42 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of TransMedics Group

Apr 9, 2025, 10:08 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of TransMedics Group

Lambster2 Aug. 5 at 1:13 AM

0 · Reply

NeverPop Aug. 5 at 1:04 AM

$TMDX really curious. do institutions just trade amongst themselves when they own 100% of the float ( not including insiders)

1 · Reply

SodApOp_PIMPski Aug. 4 at 11:55 PM

$TMDX 50dma showing signs it could be new support... a close above 145 will bring a new ATH

0 · Reply

Kenwonc Aug. 4 at 7:10 PM

$TMDX Ty to all the shorts! Ty keep holding do not close.

0 · Reply

kindness123 Aug. 4 at 5:46 PM

$TMDX

0 · Reply

buylowandwait Aug. 4 at 5:03 PM

0 · Reply

Lets_Go_Brndn Aug. 4 at 3:52 PM

$TMDX $150+ it’s coming !!!

0 · Reply

sk7887 Aug. 4 at 3:45 PM

$BLDE Interesting thought out there on Blade being a takeout candidate by $TMDX at a sweet premium: https://twitter.com/sean3333a/status/1952393903597850907?s=46&t=Eoegu7w60cNDYtBO28U9LQ

1 · Reply

TriGuy8542 Aug. 4 at 3:23 PM

$TMDX damn, well I guess I’ll have to load the boat when we see a dip, whenever that is

2 · Reply

SodApOp_PIMPski Aug. 4 at 3:08 PM

$TMDX running away

0 · Reply

shitzushimazu Aug. 4 at 2:21 PM

$TMDX oh come on

0 · Reply

NeverPop Aug. 4 at 2:15 PM

$TMDX shorts will try all the tricks to shake retail out and hit stop loses.

0 · Reply

ItComes Aug. 4 at 2:03 PM

$TMDX A MONSTER!

0 · Reply

YouAndUs Aug. 4 at 1:56 PM

$TMDX Like many high growth companies, the hardest part as an investor is holding on while it all unfolds. TMDX could double based on reasonable growth projections and it would still be cheap in 2028 if international growth and next-gen platforms kick in.

0 · Reply

deetmesquite Aug. 4 at 1:54 PM

$BLDE I originally bought this company as a hedge to $TMDX. Their passenger business was secondary in my mind, but I do find the sale to be a little incongruent to what the CEO had been claiming about their infrastructure moat, etc. Sold half my position at 90% profit but will ride the remaining out. Not bullish, not bearish.

0 · Reply

TriGuy8542 Aug. 4 at 1:51 PM

$TMDX trials to start in the fourth quarter. Heart trial to have over 650 transplants. So I expect maybe 100-150 in Q4 ranking up faster in next quarters with FDA ADCOM in Q4 2025 and approval in Q1 2027 at the latest. In 2026 they launch internationally and in 2027 the launch of Kidney trials will occur. There are plenty of catalysts now to ensure their growth continues to skyrocket through 2029. My original thesis was for this company to be worth $32B, but likely it gets higher.

0 · Reply

SodApOp_PIMPski Aug. 4 at 1:46 PM

$TMDX like to.see this come back to 120 to fill the gap before heading up

0 · Reply